Report Detail
Global Overactive Bladder (OAB) Therapeutics Market Insights, Forecast to 2025
- RnM3518443 |
- 12 June, 2019 |
- Global |
- 116 Pages |
- QYResearch |
- Pharma & Healthcare
Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.
Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.
The global Overactive Bladder (OAB) Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Overactive Bladder (OAB) Therapeutics market based on company, product type, end user and key regions.
This report studies the global market size of Overactive Bladder (OAB) Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Overactive Bladder (OAB) Therapeutics in these regions.
This research report categorizes the global Overactive Bladder (OAB) Therapeutics market by top players/brands, region, type and end user. This report also studies the global Overactive Bladder (OAB) Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Market size by Product
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Market size by End User
Hosptial
Clinci
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Overactive Bladder (OAB) Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Overactive Bladder (OAB) Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Overactive Bladder (OAB) Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Overactive Bladder (OAB) Therapeutics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Overactive Bladder (OAB) Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Overactive Bladder (OAB) Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Overactive Bladder (OAB) Therapeutics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Product
- 1.4.2 Anticholinergic Agents
- 1.4.3 Beta-3 Adrenoreceptor Agonists
- 1.5 Market by End User
- 1.5.1 Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by End User
- 1.5.2 Hosptial
- 1.5.3 Clinci
- 1.5.4 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Overactive Bladder (OAB) Therapeutics Market Size
- 2.1.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2014-2025
- 2.1.2 Global Overactive Bladder (OAB) Therapeutics Sales 2014-2025
- 2.2 Overactive Bladder (OAB) Therapeutics Growth Rate by Regions
- 2.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Regions
- 2.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Overactive Bladder (OAB) Therapeutics Sales by Manufacturers
- 3.1.1 Overactive Bladder (OAB) Therapeutics Sales by Manufacturers
- 3.1.2 Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers
- 3.1.3 Global Overactive Bladder (OAB) Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers
- 3.2.1 Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.3 Overactive Bladder (OAB) Therapeutics Price by Manufacturers
- 3.4 Overactive Bladder (OAB) Therapeutics Manufacturing Base Distribution, Product Types
- 3.4.1 Overactive Bladder (OAB) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Overactive Bladder (OAB) Therapeutics Product Type
- 3.4.3 Date of International Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Overactive Bladder (OAB) Therapeutics Sales by Product
- 4.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Product
- 4.3 Overactive Bladder (OAB) Therapeutics Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Overactive Bladder (OAB) Therapeutics Breakdown Data by End User
6 North America
- 6.1 North America Overactive Bladder (OAB) Therapeutics by Countries
- 6.1.1 North America Overactive Bladder (OAB) Therapeutics Sales by Countries
- 6.1.2 North America Overactive Bladder (OAB) Therapeutics Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Overactive Bladder (OAB) Therapeutics by Product
- 6.3 North America Overactive Bladder (OAB) Therapeutics by End User
7 Europe
- 7.1 Europe Overactive Bladder (OAB) Therapeutics by Countries
- 7.1.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Countries
- 7.1.2 Europe Overactive Bladder (OAB) Therapeutics Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Overactive Bladder (OAB) Therapeutics by Product
- 7.3 Europe Overactive Bladder (OAB) Therapeutics by End User
8 Asia Pacific
- 8.1 Asia Pacific Overactive Bladder (OAB) Therapeutics by Countries
- 8.1.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Countries
- 8.1.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Overactive Bladder (OAB) Therapeutics by Product
- 8.3 Asia Pacific Overactive Bladder (OAB) Therapeutics by End User
9 Central & South America
- 9.1 Central & South America Overactive Bladder (OAB) Therapeutics by Countries
- 9.1.1 Central & South America Overactive Bladder (OAB) Therapeutics Sales by Countries
- 9.1.2 Central & South America Overactive Bladder (OAB) Therapeutics Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Overactive Bladder (OAB) Therapeutics by Product
- 9.3 Central & South America Overactive Bladder (OAB) Therapeutics by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics by Countries
- 10.1.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Countries
- 10.1.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics by Product
- 10.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics by End User
11 Company Profiles
- 11.1 Allergan
- 11.1.1 Allergan Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered
- 11.1.5 Allergan Recent Development
- 11.2 Astellas Pharma
- 11.2.1 Astellas Pharma Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Products Offered
- 11.2.5 Astellas Pharma Recent Development
- 11.3 Hisamitsu Pharmaceutical
- 11.3.1 Hisamitsu Pharmaceutical Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
- 11.3.5 Hisamitsu Pharmaceutical Recent Development
- 11.4 Pfizer
- 11.4.1 Pfizer Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Products Offered
- 11.4.5 Pfizer Recent Development
- 11.5 Ferring
- 11.5.1 Ferring Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Ferring Overactive Bladder (OAB) Therapeutics Products Offered
- 11.5.5 Ferring Recent Development
- 11.6 GlaxoSmithKline
- 11.6.1 GlaxoSmithKline Company Details
- 11.6.2 Company Business Overview
- 11.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Products Offered
- 11.6.5 GlaxoSmithKline Recent Development
- 11.7 Ion Channel Innovations
- 11.7.1 Ion Channel Innovations Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Products Offered
- 11.7.5 Ion Channel Innovations Recent Development
- 11.8 Kwang Dong Pharmaceutical
- 11.8.1 Kwang Dong Pharmaceutical Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
- 11.8.5 Kwang Dong Pharmaceutical Recent Development
- 11.9 Lanzhou Institute of Biological Products
- 11.9.1 Lanzhou Institute of Biological Products Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Products Offered
- 11.9.5 Lanzhou Institute of Biological Products Recent Development
- 11.10 Merck
- 11.10.1 Merck Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Merck Overactive Bladder (OAB) Therapeutics Products Offered
- 11.10.5 Merck Recent Development
- 11.11 ONO Pharmaceutical
- 11.12 Sanofi
- 11.13 Tengion
- 11.14 Teva Pharmaceutical Industries
12 Future Forecast
- 12.1 Overactive Bladder (OAB) Therapeutics Market Forecast by Regions
- 12.1.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Regions 2019-2025
- 12.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Regions 2019-2025
- 12.2 Overactive Bladder (OAB) Therapeutics Market Forecast by Product
- 12.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Product 2019-2025
- 12.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Product 2019-2025
- 12.3 Overactive Bladder (OAB) Therapeutics Market Forecast by End User
- 12.4 North America Overactive Bladder (OAB) Therapeutics Forecast
- 12.5 Europe Overactive Bladder (OAB) Therapeutics Forecast
- 12.6 Asia Pacific Overactive Bladder (OAB) Therapeutics Forecast
- 12.7 Central & South America Overactive Bladder (OAB) Therapeutics Forecast
- 12.8 Middle East and Africa Overactive Bladder (OAB) Therapeutics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Overactive Bladder (OAB) Therapeutics Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Overactive Bladder (OAB) Therapeutics . Industry analysis & Market Report on Overactive Bladder (OAB) Therapeutics is a syndicated market report, published as Global Overactive Bladder (OAB) Therapeutics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Overactive Bladder (OAB) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
